nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Acyl chain remodeling of CL—TAZ—dilated cardiomyopathy	0.0433	0.114	CbGpPWpGaD
Orlistat—ABHD16A—myocardium—dilated cardiomyopathy	0.0257	0.181	CbGeAlD
Orlistat—ABHD12—myocardium—dilated cardiomyopathy	0.0241	0.169	CbGeAlD
Orlistat—DAGLB—heart—dilated cardiomyopathy	0.0236	0.166	CbGeAlD
Orlistat—Menstruation irregular—Spironolactone—dilated cardiomyopathy	0.0196	0.0424	CcSEcCtD
Orlistat—Gastrointestinal symptom NOS—Spironolactone—dilated cardiomyopathy	0.0185	0.04	CcSEcCtD
Orlistat—PNLIP—heart—dilated cardiomyopathy	0.0168	0.118	CbGeAlD
Orlistat—ABHD12—heart—dilated cardiomyopathy	0.0168	0.118	CbGeAlD
Orlistat—Bullous eruption—Furosemide—dilated cardiomyopathy	0.0149	0.0323	CcSEcCtD
Orlistat—PLA2G4A—Enalapril—Lisinopril—dilated cardiomyopathy	0.0144	1	CbGdCrCtD
Orlistat—ABHD12—cardiac atrium—dilated cardiomyopathy	0.0144	0.101	CbGeAlD
Orlistat—FASN—heart—dilated cardiomyopathy	0.0141	0.0991	CbGeAlD
Orlistat—PLA2G7—Lissencephaly gene (LIS1) in neuronal migration and development—RAC1—dilated cardiomyopathy	0.0138	0.0361	CbGpPWpGaD
Orlistat—Diabetic—Lisinopril—dilated cardiomyopathy	0.0133	0.0287	CcSEcCtD
Orlistat—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.0123	0.0267	CcSEcCtD
Orlistat—DAGLB—N-cadherin signaling events—GJA1—dilated cardiomyopathy	0.0122	0.0319	CbGpPWpGaD
Orlistat—DAGLA—N-cadherin signaling events—GJA1—dilated cardiomyopathy	0.0122	0.0319	CbGpPWpGaD
Orlistat—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.00997	0.0216	CcSEcCtD
Orlistat—PLA2G7—Peptide hormone metabolism—ACE—dilated cardiomyopathy	0.00927	0.0243	CbGpPWpGaD
Orlistat—DAGLB—N-cadherin signaling events—RAC1—dilated cardiomyopathy	0.00927	0.0243	CbGpPWpGaD
Orlistat—DAGLA—N-cadherin signaling events—RAC1—dilated cardiomyopathy	0.00927	0.0243	CbGpPWpGaD
Orlistat—Appetite absent—Lisinopril—dilated cardiomyopathy	0.0089	0.0193	CcSEcCtD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.00729	0.0191	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.00729	0.0191	CbGpPWpGaD
Orlistat—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00709	0.0154	CcSEcCtD
Orlistat—FASN—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00707	0.0185	CbGpPWpGaD
Orlistat—Gastritis—Spironolactone—dilated cardiomyopathy	0.00697	0.0151	CcSEcCtD
Orlistat—PLA2G4A—heart—dilated cardiomyopathy	0.00677	0.0476	CbGeAlD
Orlistat—Drug interaction—Furosemide—dilated cardiomyopathy	0.00636	0.0138	CcSEcCtD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.00632	0.0166	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.00632	0.0166	CbGpPWpGaD
Orlistat—Renal failure—Spironolactone—dilated cardiomyopathy	0.00597	0.0129	CcSEcCtD
Orlistat—PLA2G7—Peptide hormone metabolism—AGT—dilated cardiomyopathy	0.00587	0.0154	CbGpPWpGaD
Orlistat—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00542	0.0117	CcSEcCtD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.00538	0.0141	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.00538	0.0141	CbGpPWpGaD
Orlistat—Urine output increased—Furosemide—dilated cardiomyopathy	0.00534	0.0116	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	0.00515	0.0135	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—TAZ—dilated cardiomyopathy	0.00515	0.0135	CbGpPWpGaD
Orlistat—PLA2G4A—Glycerophospholipid biosynthesis—TAZ—dilated cardiomyopathy	0.00506	0.0132	CbGpPWpGaD
Orlistat—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00493	0.0107	CcSEcCtD
Orlistat—Polyuria—Furosemide—dilated cardiomyopathy	0.00488	0.0106	CcSEcCtD
Orlistat—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00487	0.0105	CcSEcCtD
Orlistat—Alopecia—Spironolactone—dilated cardiomyopathy	0.00482	0.0104	CcSEcCtD
Orlistat—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00478	0.0103	CcSEcCtD
Orlistat—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00456	0.00988	CcSEcCtD
Orlistat—Thirst—Furosemide—dilated cardiomyopathy	0.0045	0.00975	CcSEcCtD
Orlistat—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00448	0.00971	CcSEcCtD
Orlistat—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.0044	0.00953	CcSEcCtD
Orlistat—Malaise—Spironolactone—dilated cardiomyopathy	0.00428	0.00926	CcSEcCtD
Orlistat—Discomfort—Spironolactone—dilated cardiomyopathy	0.00399	0.00864	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00398	0.0104	CbGpPWpGaD
Orlistat—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.0039	0.00845	CcSEcCtD
Orlistat—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00387	0.00838	CcSEcCtD
Orlistat—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00386	0.00836	CcSEcCtD
Orlistat—DAGLB—Hemostasis—TTN—dilated cardiomyopathy	0.00376	0.00985	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TTN—dilated cardiomyopathy	0.00376	0.00985	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00374	0.0098	CbGpPWpGaD
Orlistat—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00373	0.00808	CcSEcCtD
Orlistat—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00371	0.00804	CcSEcCtD
Orlistat—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.0037	0.00801	CcSEcCtD
Orlistat—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00363	0.00786	CcSEcCtD
Orlistat—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00358	0.00775	CcSEcCtD
Orlistat—Eczema—Lisinopril—dilated cardiomyopathy	0.00358	0.00775	CcSEcCtD
Orlistat—FASN—AMPK Signaling—RPS6KB1—dilated cardiomyopathy	0.00357	0.00936	CbGpPWpGaD
Orlistat—PLA2G4A—Phospholipid metabolism—TAZ—dilated cardiomyopathy	0.00353	0.00924	CbGpPWpGaD
Orlistat—DAGLB—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00337	0.00882	CbGpPWpGaD
Orlistat—DAGLA—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00337	0.00882	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00334	0.00724	CcSEcCtD
Orlistat—Arthritis—Lisinopril—dilated cardiomyopathy	0.00331	0.00717	CcSEcCtD
Orlistat—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00329	0.00714	CcSEcCtD
Orlistat—DAGLA—Hemostasis—ACTN2—dilated cardiomyopathy	0.00326	0.00854	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—ACTN2—dilated cardiomyopathy	0.00326	0.00854	CbGpPWpGaD
Orlistat—Renal failure—Furosemide—dilated cardiomyopathy	0.00325	0.00703	CcSEcCtD
Orlistat—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00322	0.00696	CcSEcCtD
Orlistat—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00319	0.00691	CcSEcCtD
Orlistat—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00312	0.00676	CcSEcCtD
Orlistat—Urticaria—Spironolactone—dilated cardiomyopathy	0.00308	0.00666	CcSEcCtD
Orlistat—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00306	0.00663	CcSEcCtD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00301	0.00789	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00301	0.00789	CbGpPWpGaD
Orlistat—FASN—p73 transcription factor network—FAS—dilated cardiomyopathy	0.00295	0.00774	CbGpPWpGaD
Orlistat—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00293	0.00634	CcSEcCtD
Orlistat—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00291	0.00629	CcSEcCtD
Orlistat—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00291	0.00629	CcSEcCtD
Orlistat—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.0029	0.00627	CcSEcCtD
Orlistat—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00285	0.00618	CcSEcCtD
Orlistat—Gastritis—Lisinopril—dilated cardiomyopathy	0.00285	0.00616	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00282	0.00738	CbGpPWpGaD
Orlistat—Influenza—Lisinopril—dilated cardiomyopathy	0.00278	0.00602	CcSEcCtD
Orlistat—Asthma—Lisinopril—dilated cardiomyopathy	0.00278	0.00602	CcSEcCtD
Orlistat—DAGLA—Hemostasis—VCL—dilated cardiomyopathy	0.00277	0.00726	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—VCL—dilated cardiomyopathy	0.00277	0.00726	CbGpPWpGaD
Orlistat—Pruritus—Spironolactone—dilated cardiomyopathy	0.00274	0.00593	CcSEcCtD
Orlistat—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00273	0.00592	CcSEcCtD
Orlistat—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00272	0.0059	CcSEcCtD
Orlistat—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00271	0.00586	CcSEcCtD
Orlistat—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00268	0.0058	CcSEcCtD
Orlistat—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00265	0.00574	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00265	0.00694	CbGpPWpGaD
Orlistat—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00258	0.00559	CcSEcCtD
Orlistat—Malnutrition—Furosemide—dilated cardiomyopathy	0.00258	0.00559	CcSEcCtD
Orlistat—Dizziness—Spironolactone—dilated cardiomyopathy	0.00256	0.00554	CcSEcCtD
Orlistat—Flatulence—Furosemide—dilated cardiomyopathy	0.00254	0.00551	CcSEcCtD
Orlistat—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00253	0.00547	CcSEcCtD
Orlistat—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00248	0.00537	CcSEcCtD
Orlistat—Depression—Lisinopril—dilated cardiomyopathy	0.00247	0.00535	CcSEcCtD
Orlistat—Vomiting—Spironolactone—dilated cardiomyopathy	0.00246	0.00533	CcSEcCtD
Orlistat—Rash—Spironolactone—dilated cardiomyopathy	0.00244	0.00529	CcSEcCtD
Orlistat—PLA2G4A—p38 MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	0.00244	0.00639	CbGpPWpGaD
Orlistat—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00244	0.00528	CcSEcCtD
Orlistat—Renal failure—Lisinopril—dilated cardiomyopathy	0.00244	0.00528	CcSEcCtD
Orlistat—Vision blurred—Furosemide—dilated cardiomyopathy	0.00243	0.00527	CcSEcCtD
Orlistat—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00243	0.00526	CcSEcCtD
Orlistat—Headache—Spironolactone—dilated cardiomyopathy	0.00243	0.00525	CcSEcCtD
Orlistat—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00241	0.00522	CcSEcCtD
Orlistat—DAGLA—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00237	0.00621	CbGpPWpGaD
Orlistat—DAGLB—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00237	0.00621	CbGpPWpGaD
Orlistat—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00234	0.00508	CcSEcCtD
Orlistat—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00232	0.00503	CcSEcCtD
Orlistat—Vertigo—Furosemide—dilated cardiomyopathy	0.00232	0.00502	CcSEcCtD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.0023	0.00603	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.0023	0.00603	CbGpPWpGaD
Orlistat—Nausea—Spironolactone—dilated cardiomyopathy	0.0023	0.00498	CcSEcCtD
Orlistat—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00222	0.00482	CcSEcCtD
Orlistat—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00221	0.00478	CcSEcCtD
Orlistat—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.0022	0.00476	CcSEcCtD
Orlistat—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00219	0.00475	CcSEcCtD
Orlistat—PLA2G4A—PDGF Pathway—RAC1—dilated cardiomyopathy	0.00219	0.00573	CbGpPWpGaD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00218	0.00473	CcSEcCtD
Orlistat—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00218	0.00472	CcSEcCtD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.00217	0.00568	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.00217	0.00568	CbGpPWpGaD
Orlistat—Dry mouth—Furosemide—dilated cardiomyopathy	0.00215	0.00465	CcSEcCtD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00212	0.00555	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00212	0.00555	CbGpPWpGaD
Orlistat—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00211	0.00456	CcSEcCtD
Orlistat—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00207	0.00447	CcSEcCtD
Orlistat—Skin disorder—Furosemide—dilated cardiomyopathy	0.00205	0.00443	CcSEcCtD
Orlistat—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00204	0.00441	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—LMNA—dilated cardiomyopathy	0.00203	0.00531	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00201	0.00525	CbGpPWpGaD
Orlistat—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.002	0.00434	CcSEcCtD
Orlistat—Alopecia—Lisinopril—dilated cardiomyopathy	0.00197	0.00426	CcSEcCtD
Orlistat—PLA2G4A—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00195	0.00512	CbGpPWpGaD
Orlistat—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00195	0.00422	CcSEcCtD
Orlistat—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00194	0.00419	CcSEcCtD
Orlistat—Flatulence—Lisinopril—dilated cardiomyopathy	0.00191	0.00413	CcSEcCtD
Orlistat—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.0019	0.00411	CcSEcCtD
Orlistat—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00189	0.0041	CcSEcCtD
Orlistat—Back pain—Lisinopril—dilated cardiomyopathy	0.00187	0.00406	CcSEcCtD
Orlistat—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00186	0.00403	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.00183	0.00481	CbGpPWpGaD
Orlistat—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00183	0.00397	CcSEcCtD
Orlistat—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00182	0.00395	CcSEcCtD
Orlistat—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00182	0.00394	CcSEcCtD
Orlistat—Fatigue—Furosemide—dilated cardiomyopathy	0.00182	0.00393	CcSEcCtD
Orlistat—Pain—Furosemide—dilated cardiomyopathy	0.0018	0.0039	CcSEcCtD
Orlistat—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.0018	0.00389	CcSEcCtD
Orlistat—PNLIP—Metabolism—ANKRD1—dilated cardiomyopathy	0.00177	0.00464	CbGpPWpGaD
Orlistat—Angioedema—Lisinopril—dilated cardiomyopathy	0.00177	0.00383	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—ACE—dilated cardiomyopathy	0.00175	0.00458	CbGpPWpGaD
Orlistat—Malaise—Lisinopril—dilated cardiomyopathy	0.00175	0.00378	CcSEcCtD
Orlistat—Vertigo—Lisinopril—dilated cardiomyopathy	0.00174	0.00377	CcSEcCtD
Orlistat—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00174	0.00376	CcSEcCtD
Orlistat—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00172	0.00373	CcSEcCtD
Orlistat—Palpitations—Lisinopril—dilated cardiomyopathy	0.00171	0.00371	CcSEcCtD
Orlistat—Cough—Lisinopril—dilated cardiomyopathy	0.00169	0.00366	CcSEcCtD
Orlistat—Urticaria—Furosemide—dilated cardiomyopathy	0.00167	0.00362	CcSEcCtD
Orlistat—PNLIP—Metabolism—TAZ—dilated cardiomyopathy	0.00167	0.00437	CbGpPWpGaD
Orlistat—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00167	0.00361	CcSEcCtD
Orlistat—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00167	0.00361	CcSEcCtD
Orlistat—Myalgia—Lisinopril—dilated cardiomyopathy	0.00165	0.00357	CcSEcCtD
Orlistat—Chest pain—Lisinopril—dilated cardiomyopathy	0.00165	0.00357	CcSEcCtD
Orlistat—Anxiety—Lisinopril—dilated cardiomyopathy	0.00164	0.00356	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00164	0.00355	CcSEcCtD
Orlistat—Discomfort—Lisinopril—dilated cardiomyopathy	0.00163	0.00353	CcSEcCtD
Orlistat—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00161	0.00349	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.00159	0.00417	CbGpPWpGaD
Orlistat—FASN—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.00159	0.00417	CbGpPWpGaD
Orlistat—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00158	0.00342	CcSEcCtD
Orlistat—Oedema—Lisinopril—dilated cardiomyopathy	0.00158	0.00342	CcSEcCtD
Orlistat—Infection—Lisinopril—dilated cardiomyopathy	0.00157	0.0034	CcSEcCtD
Orlistat—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00155	0.00336	CcSEcCtD
Orlistat—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00154	0.00332	CcSEcCtD
Orlistat—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00153	0.00331	CcSEcCtD
Orlistat—Asthenia—Furosemide—dilated cardiomyopathy	0.00151	0.00327	CcSEcCtD
Orlistat—PNLIP—Metabolism—SDHA—dilated cardiomyopathy	0.00151	0.00395	CbGpPWpGaD
Orlistat—Pruritus—Furosemide—dilated cardiomyopathy	0.00149	0.00323	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—RAC1—dilated cardiomyopathy	0.00149	0.0039	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.00147	0.00385	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.00147	0.00385	CbGpPWpGaD
Orlistat—PLA2G4A—PDGF Pathway—RAF1—dilated cardiomyopathy	0.00145	0.0038	CbGpPWpGaD
Orlistat—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00144	0.00312	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00144	0.00312	CcSEcCtD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.00144	0.00377	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.00144	0.00377	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—RAC1—dilated cardiomyopathy	0.00144	0.00376	CbGpPWpGaD
Orlistat—FASN—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.00143	0.00375	CbGpPWpGaD
Orlistat—Insomnia—Lisinopril—dilated cardiomyopathy	0.00143	0.0031	CcSEcCtD
Orlistat—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00142	0.00307	CcSEcCtD
Orlistat—Dizziness—Furosemide—dilated cardiomyopathy	0.00139	0.00302	CcSEcCtD
Orlistat—DAGLB—Hemostasis—ITGB1—dilated cardiomyopathy	0.00139	0.00365	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—ITGB1—dilated cardiomyopathy	0.00139	0.00365	CbGpPWpGaD
Orlistat—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00139	0.00301	CcSEcCtD
Orlistat—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00137	0.00298	CcSEcCtD
Orlistat—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00136	0.00295	CcSEcCtD
Orlistat—Fatigue—Lisinopril—dilated cardiomyopathy	0.00136	0.00295	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.00135	0.00354	CbGpPWpGaD
Orlistat—Pain—Lisinopril—dilated cardiomyopathy	0.00135	0.00293	CcSEcCtD
Orlistat—Vomiting—Furosemide—dilated cardiomyopathy	0.00134	0.0029	CcSEcCtD
Orlistat—Rash—Furosemide—dilated cardiomyopathy	0.00133	0.00288	CcSEcCtD
Orlistat—Dermatitis—Furosemide—dilated cardiomyopathy	0.00133	0.00287	CcSEcCtD
Orlistat—Headache—Furosemide—dilated cardiomyopathy	0.00132	0.00286	CcSEcCtD
Orlistat—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.0013	0.00282	CcSEcCtD
Orlistat—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00129	0.0028	CcSEcCtD
Orlistat—Urticaria—Lisinopril—dilated cardiomyopathy	0.00126	0.00272	CcSEcCtD
Orlistat—FASN—Metabolism—ANKRD1—dilated cardiomyopathy	0.00125	0.00329	CbGpPWpGaD
Orlistat—Nausea—Furosemide—dilated cardiomyopathy	0.00125	0.00271	CcSEcCtD
Orlistat—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00125	0.00271	CcSEcCtD
Orlistat—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00125	0.00271	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00125	0.00327	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00125	0.00327	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00125	0.00327	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00125	0.00327	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00121	0.00317	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—CD36—dilated cardiomyopathy	0.00119	0.00311	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—CD36—dilated cardiomyopathy	0.00119	0.00311	CbGpPWpGaD
Orlistat—FASN—Metabolism—TAZ—dilated cardiomyopathy	0.00118	0.00309	CbGpPWpGaD
Orlistat—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00116	0.00252	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00116	0.00304	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00116	0.00304	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00114	0.00298	CbGpPWpGaD
Orlistat—Asthenia—Lisinopril—dilated cardiomyopathy	0.00113	0.00246	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00113	0.00297	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00113	0.00297	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00113	0.00297	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00113	0.00297	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00112	0.00294	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00112	0.00294	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—RAC1—dilated cardiomyopathy	0.00112	0.00293	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—RAC1—dilated cardiomyopathy	0.00112	0.00293	CbGpPWpGaD
Orlistat—Pruritus—Lisinopril—dilated cardiomyopathy	0.00112	0.00242	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—AGT—dilated cardiomyopathy	0.00111	0.00291	CbGpPWpGaD
Orlistat—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00108	0.00234	CcSEcCtD
Orlistat—FASN—Metabolism—SDHA—dilated cardiomyopathy	0.00107	0.00279	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00105	0.00276	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00105	0.00276	CbGpPWpGaD
Orlistat—Dizziness—Lisinopril—dilated cardiomyopathy	0.00105	0.00226	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00102	0.00267	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00102	0.00267	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—RAF1—dilated cardiomyopathy	0.00101	0.00266	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.00101	0.00264	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.00101	0.00264	CbGpPWpGaD
Orlistat—Vomiting—Lisinopril—dilated cardiomyopathy	0.001	0.00218	CcSEcCtD
Orlistat—Rash—Lisinopril—dilated cardiomyopathy	0.000996	0.00216	CcSEcCtD
Orlistat—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000996	0.00216	CcSEcCtD
Orlistat—Headache—Lisinopril—dilated cardiomyopathy	0.00099	0.00214	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—RAF1—dilated cardiomyopathy	0.000988	0.00259	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.00096	0.00251	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.00096	0.00251	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—RAF1—dilated cardiomyopathy	0.000952	0.00249	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TTN—dilated cardiomyopathy	0.000946	0.00248	CbGpPWpGaD
Orlistat—Nausea—Lisinopril—dilated cardiomyopathy	0.000939	0.00203	CcSEcCtD
Orlistat—PNLIP—Disease—NPPA—dilated cardiomyopathy	0.000921	0.00241	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000919	0.00241	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.00091	0.00239	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.00091	0.00239	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000895	0.00235	CbGpPWpGaD
Orlistat—PNLIP—Disease—PSEN2—dilated cardiomyopathy	0.000892	0.00234	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000871	0.00228	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000871	0.00228	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—RAC1—dilated cardiomyopathy	0.000861	0.00226	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000827	0.00217	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000827	0.00217	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ACTN2—dilated cardiomyopathy	0.00082	0.00215	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000806	0.00211	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000754	0.00198	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000754	0.00198	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—RAF1—dilated cardiomyopathy	0.000742	0.00194	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—RAF1—dilated cardiomyopathy	0.000742	0.00194	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000707	0.00185	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000707	0.00185	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VCL—dilated cardiomyopathy	0.000697	0.00183	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000675	0.00177	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000675	0.00177	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000669	0.00175	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000669	0.00175	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000669	0.00175	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000669	0.00175	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—EGFR—dilated cardiomyopathy	0.000653	0.00171	CbGpPWpGaD
Orlistat—FASN—Disease—NPPA—dilated cardiomyopathy	0.000652	0.00171	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.00065	0.0017	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000649	0.0017	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000642	0.00168	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000642	0.00168	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000633	0.00166	CbGpPWpGaD
Orlistat—FASN—Disease—PSEN2—dilated cardiomyopathy	0.000631	0.00165	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000626	0.00164	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000625	0.00164	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000622	0.00163	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000622	0.00163	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000613	0.00161	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000613	0.00161	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000613	0.00161	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000603	0.00158	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000603	0.00158	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.000579	0.00152	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—RAF1—dilated cardiomyopathy	0.000571	0.0015	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.00057	0.00149	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000555	0.00145	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000555	0.00145	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.000546	0.00143	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ANKRD1—dilated cardiomyopathy	0.000538	0.00141	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000516	0.00135	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000515	0.00135	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000515	0.00135	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TAZ—dilated cardiomyopathy	0.000506	0.00133	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000499	0.00131	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000488	0.00128	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000488	0.00128	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SDHA—dilated cardiomyopathy	0.000458	0.0012	CbGpPWpGaD
Orlistat—PNLIP—Disease—RAC1—dilated cardiomyopathy	0.000449	0.00118	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000427	0.00112	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000426	0.00111	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000426	0.00111	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.00042	0.0011	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.00042	0.0011	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—GPX1—dilated cardiomyopathy	0.000409	0.00107	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000407	0.00107	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000405	0.00106	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CD36—dilated cardiomyopathy	0.000399	0.00104	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000379	0.000993	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000379	0.000993	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AGT—dilated cardiomyopathy	0.000362	0.000949	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AGT—dilated cardiomyopathy	0.000362	0.000949	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.000362	0.000948	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AGT—dilated cardiomyopathy	0.000359	0.00094	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ITGB1—dilated cardiomyopathy	0.00035	0.000917	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000348	0.000911	CbGpPWpGaD
Orlistat—FASN—Disease—RAC1—dilated cardiomyopathy	0.000317	0.000832	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000314	0.000823	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AGT—dilated cardiomyopathy	0.0003	0.000786	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—CD36—dilated cardiomyopathy	0.000299	0.000782	CbGpPWpGaD
Orlistat—PNLIP—Disease—RAF1—dilated cardiomyopathy	0.000297	0.000779	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000292	0.000765	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000292	0.000765	CbGpPWpGaD
Orlistat—FASN—Metabolism—GPX1—dilated cardiomyopathy	0.00029	0.000759	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000285	0.000747	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000285	0.000747	CbGpPWpGaD
Orlistat—FASN—Metabolism—CD36—dilated cardiomyopathy	0.000282	0.000739	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—RAC1—dilated cardiomyopathy	0.000281	0.000737	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000279	0.000731	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000279	0.000731	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000272	0.000712	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000266	0.000696	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000265	0.000694	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000257	0.000673	CbGpPWpGaD
Orlistat—FASN—Metabolism—AGT—dilated cardiomyopathy	0.000254	0.000665	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000251	0.000659	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000251	0.000659	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000245	0.000641	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000219	0.000574	CbGpPWpGaD
Orlistat—FASN—Disease—RAF1—dilated cardiomyopathy	0.00021	0.000551	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000208	0.000546	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000208	0.000545	CbGpPWpGaD
Orlistat—PNLIP—Disease—EGFR—dilated cardiomyopathy	0.000204	0.000534	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.00019	0.000497	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—RAF1—dilated cardiomyopathy	0.000187	0.000489	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000172	0.000452	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000172	0.000452	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000168	0.000441	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000168	0.000441	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000161	0.000423	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000157	0.00041	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000154	0.000404	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000152	0.000397	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—dilated cardiomyopathy	0.000144	0.000378	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000143	0.000374	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.00013	0.000339	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000126	0.00033	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GPX1—dilated cardiomyopathy	0.000124	0.000326	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000123	0.000322	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CD36—dilated cardiomyopathy	0.000121	0.000317	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000118	0.00031	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AGT—dilated cardiomyopathy	0.000109	0.000286	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000107	0.000281	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000107	0.000281	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000106	0.000277	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RAC1—dilated cardiomyopathy	9.54e-05	0.00025	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGT—dilated cardiomyopathy	9.11e-05	0.000239	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—dilated cardiomyopathy	7.34e-05	0.000192	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RAF1—dilated cardiomyopathy	6.32e-05	0.000166	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—dilated cardiomyopathy	4.34e-05	0.000114	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.91e-05	7.63e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.83e-05	7.43e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.55e-05	6.69e-05	CbGpPWpGaD
